Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Phase 3
Completed
NCT05198934
| Condition | Colorectal Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Amgen |
|---|
| Status | Completed |
|---|
| Enrollment | 160 participants |
|---|
| Interventions | Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib |
|---|
| Start date | Apr 19, 2022 |
|---|
| Completion date | Jul 16, 2025 |
|---|
| Results posted | Jul 22, 2026 |
|---|
Summary
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR
From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months · months
| Trifluridine and Tipiracil or Regorafenib | 2.04 months |
|---|
| Sotorasib 240 mg + Panitumumab | 3.91 months |
|---|
| Sotorasib 960 mg + Panitumumab | 5.62 months |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.